National

topics

politics-policy

epstein-files

donald-trump

2026-midterm-elections

immigration

behind-the-curtain

race-and-equity

technology

privacy-tech-regulation

automation-and-ai

tiktok-news

big-tech

social-media

cybersecurity

economy

social-security

inflation

tariffs

federal-reserve

jobs

transportation

business

stock-market-news

retail-news

crypto

media

elon-musk

dealmaking

health

rfk-jr

drug-prices

axios-explains-abortion

public-health

world

israel

axios-explains-ukraine

iran

russia

china

energy-climate

nuclear-energy

climate-energy-policy

climate-change

extreme-weather

alternative-energy

electric-vehicles

science

emerging-tech

biomedicine

newsletters

pittsburgh

atlanta

san-diego

charlotte

boulder

washington-dc

kansas-city

dallas

denver

detroit

des-moines

austin

boston

chicago

cleveland

columbus

houston

indianapolis

miami

nashville

new-orleans

nw-arkansas

philadelphia

phoenix

portland

richmond

salt-lake-city

san-antonio

san-francisco

seattle

tampa-bay

twin-cities

raleigh

huntsville

colorado-springs

axios-local

axios-pro

axios-live

the-axios-show

A new study found that experimental drugs made by Eli Lilly and Roche didn't help people with a rare, inherited form of Alzheimer's, the Wall Street Journal reports.

Why it matters: Alzheimer's is a devastating disease, and drug after drug keeps failing to do more than temporarily alleviate its symptoms.

Yes, but: The prevalence of the disease, combined with how it has become somewhat of a holy grail for drugmakers, means that the industry has far from given up on it.

Last year, 405 drugs were being studied for the disease, and increase from 381 in 2018.

Go deeper: The outlook for Alzheimer's research keeps getting bleaker

Another setback for an experimental Alzheimer's drug

It has become somewhat of a holy grail for drugmakers.

Health Care

Alzheimer's disease

Get news and analysis on the politics and business of health care

Sign up for the Vitals newsletter

A new study found that experimental drugs made by Eli Lilly and Roche didn&#x27;t help people with a rare, inherited form of Alzheimer&#x27;s, <a class="gtmContentClick" data-vars-link-text="the Wall Street Journal reports" data-vars-click-url="https://link.axios.com/click/19412602.56465/aHR0cHM6Ly93d3cud3NqLmNvbS9hcnRpY2xlcy9saWxseS1yb2NoZS1kcnVncy1mYWlsLXRvLXN0eW1pZS1pbmhlcml0ZWQtZm9ybS1vZi1hbHpoZWltZXJzLTExNTgxMzUwMjc2P21vZD1ocF9saXN0YV9wb3M1JnV0bV9zb3VyY2U9bmV3c2xldHRlciZ1dG1fbWVkaXVtPWVtYWlsJnV0bV9jYW1wYWlnbj1uZXdzbGV0dGVyX2F4aW9zdml0YWxzJnN0cmVhbT10b3A/5c90f2c505e94e65b176e000B62abd301" data-vars-content-id="43c80bcc-8062-489d-82b7-bd2d060fda57" data-vars-headline="Another setback for an experimental Alzheimer&#x27;s drug" data-vars-event-category="story" data-vars-sub-category="story" data-vars-item="in_content_link" href="https://link.axios.com/click/19412602.56465/aHR0cHM6Ly93d3cud3NqLmNvbS9hcnRpY2xlcy9saWxseS1yb2NoZS1kcnVncy1mYWlsLXRvLXN0eW1pZS1pbmhlcml0ZWQtZm9ybS1vZi1hbHpoZWltZXJzLTExNTgxMzUwMjc2P21vZD1ocF9saXN0YV9wb3M1JnV0bV9zb3VyY2U9bmV3c2xldHRlciZ1dG1fbWVkaXVtPWVtYWlsJnV0bV9jYW1wYWlnbj1uZXdzbGV0dGVyX2F4aW9zdml0YWxzJnN0cmVhbT10b3A/5c90f2c505e94e65b176e000B62abd301" target="_self">the Wall Street Journal reports</a>.Why it matters: Alzheimer&#x27;s is a devastating disease, and drug after drug keeps failing to do more than temporarily alleviate its symptoms.

The U.S. health system faces critical questions about cost, access and equity. Technological advances and new discoveries about diseases like cancer and Alzheimer’s are transforming patient care and reshaping public health.

Health

Another setback for an experimental Alzheimer's drug

What to read next